This specific effect of PKC modulation in diabetes was also observed in the PRAs, an effect that was reproduced when using a different PDE5 inhibitor, tadalafil, in both the CC and PRAs of diabetic patients with ED. Here, PDE5A is linked to diabetes mellitus.